Close Menu

NEW YORK – BioSpyder Technologies on Wednesday filed a civil action in  US District Court for the Northern District of California seeking a declaratory judgement that the firm's TempO-Seq gene expression profiling assay does not infringe a patent held by HTG Molecular Diagnostics.

BioSpyder's actions relates to US Patent No. 8,741,564 held by HTG covering a quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements. 

The Carlsbad, California-startup firm said that HTG has repeatedly and baselessly asserted that BioSpyder has infringed the '564 patent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.